---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-252207"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:55:32.000398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance

## Summary
- Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.
- LYBALVI sales $98.2M (+32% YoY); ARISTADA $98.1M (+16% YoY); VIVITROL $121.1M (+7% YoY).
- GAAP net income $82.8M vs $92.4M in Q3 2024; diluted EPS $0.49.
- FY2025 revenue guidance raised to $1.43-1.49B from $1.34-1.43B; GAAP net income now $230-250M.
- CEO highlighted proposed Avadel acquisition and positive phase 2 data for alixorexton in narcolepsy.

## SEC filing metadata
- accession: 0001193125-25-252207
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/0001193125-25-252207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/alks-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-252207
- JSON: https://secwatch.observer/filing/0001193125-25-252207.json
- Plain text: https://secwatch.observer/filing/0001193125-25-252207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.